Zoetis [ZTS] vs United Therapeutics [UTHR] Detailed Stock Comparison

Zoetis Inc.

NYSE
Loading...

United Therapeutics Corporation

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Zoetis Inc. wins in 8 metrics, United Therapeutics Corporation wins in 12 metrics, with 0 ties. United Therapeutics Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Zoetis Inc. United Therapeutics Corporation Better
P/E Ratio (TTM) 19.58 20.60 Zoetis Inc.
Price-to-Book Ratio 15.04 3.53 United Therapeutics Corporation
Debt-to-Equity Ratio 279.59 0.53 United Therapeutics Corporation
PEG Ratio 2.81 0.83 United Therapeutics Corporation
EV/EBITDA 13.96 13.90 United Therapeutics Corporation
Profit Margin (TTM) 28.24% 41.94% United Therapeutics Corporation
Operating Margin (TTM) 34.69% 45.23% United Therapeutics Corporation
EBITDA Margin (TTM) 34.69% 45.23% United Therapeutics Corporation
Return on Equity 65.99% 19.72% Zoetis Inc.
Return on Assets (TTM) 15.26% 12.44% Zoetis Inc.
Free Cash Flow (TTM) $2.28B $1.04B Zoetis Inc.
Dividend Yield 1.21% N/A N/A
1-Year Return -51.58% 92.68% United Therapeutics Corporation
Price-to-Sales Ratio (TTM) 5.26 7.91 Zoetis Inc.
Enterprise Value $56.75B $22.28B Zoetis Inc.
EV/Revenue Ratio 6.00 7.00 Zoetis Inc.
Gross Profit Margin (TTM) 70.17% 86.91% United Therapeutics Corporation
Revenue per Share (TTM) $21 $72 United Therapeutics Corporation
Earnings per Share (Diluted) $6.02 $27.88 United Therapeutics Corporation
Beta (Stock Volatility) 0.97 0.75 United Therapeutics Corporation
Short % of Float 4.06% 8.58% Zoetis Inc.

Zoetis Inc. vs United Therapeutics Corporation Stock Performance Analysis

Loading Price Chart...

ZTS
UTHR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Zoetis Inc.1.51%0.16%3.42%-31.08%-32.94%-36.81%
United Therapeutics Corporation0.66%0.90%-3.34%2.86%9.85%10.64%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Zoetis Inc.-51.58%-53.40%-57.08%71.34%156.59%156.59%
United Therapeutics Corporation92.68%137.11%205.88%434.68%903.79%2,026.01%

Performance & Financial Health Analysis: Zoetis Inc. vs United Therapeutics Corporation

MetricZTSUTHR
Market Information
Market Cap i$49.75B$25.11B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,727,710464,464
90 Day Avg. Volume i3,835,940635,891
Last Close$167.10$549.57
52 Week Range$139.70 - $200.33$272.12 - $609.35
% from 52W High-16.59%-9.81%
All-Time High$249.27 (Dec 27, 2021)$609.35 (May 06, 2026)
% from All-Time High-32.96%-9.81%
Growth Metrics
Quarterly Revenue Growth0.03%0.07%
Quarterly Earnings Growth0.04%0.21%
Financial Health
Profit Margin (TTM) i0.28%0.42%
Operating Margin (TTM) i0.35%0.45%
Return on Equity (TTM) i0.66%0.20%
Debt to Equity (MRQ) i279.590.53
Cash & Liquidity
Book Value per Share (MRQ)$7.84$162.60
Cash per Share (MRQ)$5.48$66.63
Operating Cash Flow (TTM) i$2.90B$1.56B
Levered Free Cash Flow (TTM) i$1.79B$583.20M
Dividends
Last 12-Month Dividend Yield i1.21%N/A
Last 12-Month Dividend i$2.03N/A

Valuation & Enterprise Metrics Analysis: Zoetis Inc. vs United Therapeutics Corporation

MetricZTS (Apr 13, 2026)UTHR (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i19.5820.60
Forward P/E i15.6116.87
PEG Ratio i2.810.83
Price to Sales (TTM) i5.267.91
Price to Book (MRQ) i15.043.53
Market Capitalization
Market Capitalization i$49.75B$25.11B
Enterprise Value i$56.75B$22.28B
Enterprise Value Metrics
Enterprise to Revenue i6.007.00
Enterprise to EBITDA i13.9613.90
Risk & Other Metrics
Beta i0.970.75
Book Value per Share (MRQ) i$7.84$162.60

Financial Statements Comparison: Zoetis Inc. vs United Therapeutics Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricZTS (2025)UTHR (2025)
Revenue/Sales i9.47B3.18B
Cost of Goods Sold i2.67B384.40M
COGS % of Revenue i28.2%12.1%
Gross Profit i6.80B2.80B
Gross Margin i71.8%87.9%
Research & Development i698.00M550.00M
Operating Income (EBIT) i3.60B1.52B
Operating Margin i38.0%47.7%
EBITDA i4.17B1.84B
EBITDA Margin i44.1%57.9%
Pre-Tax Income i3.36B1.71B
Pre-Tax Income % of Revenue i35.5%53.9%
Income Tax i687.00M379.20M
Income Tax % of Revenue i7.3%11.9%
Net Income (Profit) i2.67B1.33B
Profit Margin i28.2%41.9%

Balance Sheet & Liquidity Metrics

MetricZTS (2025)UTHR (2025)
Cash & Equivalents i2.31B1.56B
Total Current Assets i6.77B3.70B
Total Current Assets % of Revenue i71.5%116.3%
Total Current Liabilities i2.24B560.60M
Total Current Liabilities % of Revenue i23.6%17.6%
Long-Term Debt i9.24BN/A
Long-Term Debt % of Revenue i97.6%0.0%
Total Shareholders Equity i3.33B7.10B
Retained Earnings i13.74B8.56B
Retained Earnings % of Revenue i145.2%268.9%
Property, Plant & Equipment i288.00M0

Cash Flow Statement Comparison

MetricZTS (2025)UTHR (2025)
Operating Cash Flow i2.78B1.44B
Operating Cash Flow % of Revenue i29.3%45.3%
Capital Expenditures iN/A-520.50M
Free Cash Flow i2.28B1.04B
FCF Margin i24.1%32.5%
Debt Repayment i-1.35B-500.00M
Common Stock Repurchase i-3.24B-1.02B

Short Interest & Institutional Ownership Analysis

MetricZTSUTHR
Shares Short i15.12M2.84M
Short Ratio i3.604.40
Short % of Float i4.06%8.58%
Shares Outstanding i424.93M43.64M
Float Shares i421.29M40.32M
% Held by Insiders i0.15%1.94%
% Held by Institutions i101.50%97.78%
% Held by Public i-1.65%0.28%

Dividend Analysis & Yield Comparison: Zoetis Inc. vs United Therapeutics Corporation

MetricZTSUTHR
Last 12-Month Dividend i$2.03N/A
Last 12-Month Dividend Yield i1.21%N/A
3-Year Avg Annual Dividend i$1.80N/A
3-Year Avg Dividend Yield i0.29%N/A
3-Year Total Dividends i$5.39N/A
Ex-Dividend DateJan 20, 2026N/A